FILE PHOTO: The brand for Biohaven Pharmaceutical Holding Firm is displayed on a display throughout the firm’s IPO on the ground of the New York Inventory Trade (NYSE) in New York, U.S., Could 4, 2017. REUTERS/Brendan McDermid
(Reuters) – Biohaven Pharmaceutical Holding Firm Ltd mentioned on Tuesday two doses of its experimental therapy for acute migraine have been efficient in decreasing complications in a big examine, sending its shares up 8% earlier than the bell.
The drug, vazegepant, belongs to a brand new class of remedies for migraine referred to as CGRP inhibitors.
Vazegepant is the primary CGRP therapy delivered in an intranasal formulation, which advantages…